{
    "root": "30b8a715-b7de-66fc-e063-6394a90a4e76",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Memantine Hydrochloride",
    "value": "20250319",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "POLYVINYL ALCOHOL",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "MEMANTINE HYDROCHLORIDE",
            "code": "JY0WD0UA60"
        }
    ],
    "indications": "memantine hydrochloride usp indicated treatment moderate severe dementia alzheimer ’ type .",
    "contraindications": "recommended starting dose memantine hydrochloride usp 5 mg daily . dose increased 5 mg increments 10 mg/day ( 5 mg twice daily ) , 15 mg/day ( 5 mg 10 mg separate doses ) , 20 mg/day ( 10 mg twice daily ) . minimum recommended interval dose increases one week . shown effective controlled trials 20 mg/day . memantine hydrochloride taken without food . patient misses single dose memantine hydrochloride , patient double next dose . next dose taken scheduled . patient fails take memantine hydrochloride several days , dosing may need resumed lower doses retitrated described . renal impairment target dose 5 mg twice daily recommended patients severe renal impairment ( creatinine clearance 5 – 29 ml/min based cockcroft-gault equation ) . hepatic impairment memantine hydrochloride administered caution patients severe hepatic impairment [ pharmacology ( 12.3 ) ] .",
    "warningsAndPrecautions": "5 mg tablets : orange , capsule shaped , biconvex , film-coated tablets “ m5 ” engraved one side plain side . bottles 60 child-resistant closure , ndc # 27241-070-06 bottle 500 , ndc # 27241-070-05 10 mg tablets : grey , capsule shaped , biconvex , film-coated tablets “ m10 ” engraved one side plain side . bottle 60 child-resistant closure , ndc # 27241-071-06 bottle 500 , ndc # 27241-071-05 store memantine hydrochloride tablets 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispense tight container .",
    "adverseReactions": "memantine hydrochloride contraindicated patients known hypersensitivity memantine hydrochloride excipients used formulation .",
    "indications_original": "Memantine hydrochloride USP is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.",
    "contraindications_original": "The recommended starting dose of memantine hydrochloride USP is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day. \n  \n                       Memantine hydrochloride can be taken with or without food. If a patient misses a single dose of memantine hydrochloride, that patient should not double up on the next dose. The next dose should be taken as scheduled. \n    If a patient fails to take memantine hydrochloride for several days, dosing may need to be resumed at lower doses and retitrated as described above. \n  \n                       Specific Populations \n  \n                     \n                     Renal Impairment\n                       A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 – 29 mL/min based on the Cockcroft-Gault equation). \n  \n                     \n                     Hepatic Impairment\n                       Memantine hydrochloride should be administered with caution to patients with severe hepatic impairment\n \n  [see Clinical Pharmacology (\n  \n   12.3)]\n \n  .",
    "warningsAndPrecautions_original": "5 mg Tablets:\n                  Orange, capsule shaped, biconvex, film-coated tablets with “m5” engraved on one side and plain on other side.\n                  Bottles of 60 with child-resistant closure, NDC # 27241-070-06 \n    Bottle of 500, NDC # 27241-070-05\n \n                  \n                  10 mg Tablets:\n                  Grey, capsule shaped, biconvex, film-coated tablets with “m10” engraved on one side and plain on other side.\n                  Bottle of 60 with child-resistant closure, NDC # 27241-071-06 \n    Bottle of 500, NDC # 27241-071-05\n \n                  \n                  Store memantine hydrochloride tablets at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight container.",
    "adverseReactions_original": "Memantine hydrochloride is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation."
}